Literature DB >> 19139822

Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.

Roy Torcuator1, Richard Zuniga, Randa Loutfi, Tom Mikkelsen.   

Abstract

Diffuse brainstem glioma carries a dismal prognosis. The current cornerstone of treatment is radiation therapy. Chemotherapy appears to be ineffective and the role of this treatment in the recurrent or progressive setting is not known. Bevacizumab and irinotecan have been reported to have shown radiographic response and improvement in progression-free survival among patients with malignant supratentorial gliomas. In this paper, we report our experience in an adult patient with progressive diffuse brainstem glioma treated with bevacizumab and irinotecan.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19139822     DOI： 10.1007/s11060-008-9782-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  24 in total

1.  Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.

Authors:  Sridharan Gururangan; Susan N Chi; Tina Young Poussaint; Arzu Onar-Thomas; Richard J Gilbertson; Sridhar Vajapeyam; Henry S Friedman; Roger J Packer; Brian N Rood; James M Boyett; Larry E Kun
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

2.  The results of radiotherapy for brainstem tumors.

Authors:  S E Schild; S L Stafford; P D Brown; C P Wood; B W Scheithauer; P J Schomberg; W W Wong; M K Lyons; E G Shaw
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

Review 3.  Brain tumors in children.

Authors:  R J Packer
Journal:  Arch Neurol       Date:  1999-04

Review 4.  Pediatric brain stem gliomas: a review.

Authors:  C R Freeman; J P Farmer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-01-15       Impact factor: 7.038

5.  Brainstem glioma: comparative study of clinico-radiological presentation, pathology and outcome in children and adults.

Authors:  S Selvapandian; V Rajshekhar; M J Chandy
Journal:  Acta Neurochir (Wien)       Date:  1999       Impact factor: 2.216

6.  Brainstem gliomas in adults: prognostic factors and classification.

Authors:  J S Guillamo; A Monjour; L Taillandier; B Devaux; P Varlet; C Haie-Meder; G L Defer; P Maison; J J Mazeron; P Cornu; J Y Delattre
Journal:  Brain       Date:  2001-12       Impact factor: 13.501

Review 7.  Practical decisions in the treatment of pediatric brain stem tumors.

Authors:  F Epstein; S Constantini
Journal:  Pediatr Neurosurg       Date:  1996       Impact factor: 1.162

8.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

9.  A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.

Authors:  Karen J Marcus; Sharon C Dutton; Patrick Barnes; C Norman Coleman; Scott L Pomeroy; Liliana Goumnerova; Amy L Billett; Mark Kieran; Nancy J Tarbell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-04-01       Impact factor: 7.038

10.  Pediatric brain stem gliomas: an update.

Authors:  G Rubin; S Michowitz; G Horev; Z Herscovici; I J Cohen; A Shuper; Z H Rappaport
Journal:  Childs Nerv Syst       Date:  1998 Apr-May       Impact factor: 1.475
View more
  6 in total

1.  Bevacizumab in adult malignant brainstem gliomas.

Authors:  Shahzad Raza; Martin Donach
Journal:  J Neurooncol       Date:  2009-06-09       Impact factor: 4.130

Review 2.  Adult brainstem gliomas.

Authors:  German Reyes-Botero; Karima Mokhtari; Nadine Martin-Duverneuil; Jean-Yves Delattre; Florence Laigle-Donadey
Journal:  Oncologist       Date:  2012-03-01

3.  Bevacizumab in recurrent high-grade pediatric gliomas.

Authors:  Ashwatha Narayana; Saroj Kunnakkat; Jeena Chacko-Mathew; Sharon Gardner; Matthias Karajannis; Shahzad Raza; Jeffrey Wisoff; Howard Weiner; David Harter; Jeffrey Allen
Journal:  Neuro Oncol       Date:  2010-04-02       Impact factor: 12.300

Review 4.  Bevacizumab as a treatment option for radiation-induced cerebral necrosis.

Authors:  Christiane Matuschek; Edwin Bölke; Jens Nawatny; Thomas K Hoffmann; Matthias Peiper; Klaus Orth; Peter Arne Gerber; Ethelyn Rusnak; Guido Lammering; Wilfried Budach
Journal:  Strahlenther Onkol       Date:  2011-01-24       Impact factor: 3.621

5.  Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review.

Authors:  Dongdong Yu; Guang Han; Huali Liu; Likun Gao; Vivek Verma
Journal:  Onco Targets Ther       Date:  2019-02-18       Impact factor: 4.147

6.  Retrospective analysis of 104 histologically proven adult brainstem gliomas: clinical symptoms, therapeutic approaches and prognostic factors.

Authors:  Thomas Reithmeier; Aanyo Kuzeawu; Bettina Hentschel; Markus Loeffler; Michael Trippel; Guido Nikkhah
Journal:  BMC Cancer       Date:  2014-02-21       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.